Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
22. Mai 2024 16:15 ET
|
Elevai Labs Inc.
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
15. Mai 2024 16:30 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
02. Mai 2024 08:30 ET
|
Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
01. Mai 2024 16:00 ET
|
Elevai Labs Inc.
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01. Mai 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
29. April 2024 09:45 ET
|
Elevai Labs Inc.
Elevai Labs Releases Global Distribution Partnership Overview: Contracts Secure $11.5M Top Line Revenue Boost
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
22. April 2024 08:00 ET
|
Elevai Labs Inc.
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
29. März 2024 12:00 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
18. März 2024 08:30 ET
|
Elevai Labs Inc.
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
24. Januar 2024 08:30 ET
|
Elevai Labs Inc.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office